UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

European journal of cancer (1990), 2024-10, p.115070, Article 115070

2024

Volltextzugriff (PDF)

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

European journal of cancer (1990), 2019-09, Vol.119, p.97-106

2019

Volltextzugriff (PDF)

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

European journal of cancer (1990), 2024-06, Vol.204, p.114073, Article 114073

2024

Volltextzugriff (PDF)

Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib

Internal Medicine, 2024, pp.2925-23

2024

Volltextzugriff (PDF)

Properties of FDA-approved small molecule protein kinase inhibitors

Pharmacological research, 2019-06, Vol.144, p.19-50

Roskoski, Robert

2019

Volltextzugriff (PDF)

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis

Cancer treatment reviews, 2022-11, Vol.110, p.102463, Article 102463

2022

Volltextzugriff (PDF)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

Oncotarget, 2020-08, Vol.11 (34), p.3188-3197

2020

Volltextzugriff (PDF)

Targeting ERK1/2 protein-serine/threonine kinases in human cancers

Pharmacological research, 2019-04, Vol.142, p.151-168

Roskoski, Robert

2019

Volltextzugriff (PDF)

Pathological Complete Response after Beacon Regimen for Recurrent Colorectal Cancer of BRAF-Mutant—Report of a Case

Nihon Rinshō Geka Gakkai zasshi, 2023, Vol.84 (5), p.773-778

2023

Volltextzugriff (PDF)

BRAF inhibition and the spectrum of granulomatous reactions

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.605-613

2022

Volltextzugriff (PDF)

2018 FDA drug approvals

Nature reviews. Drug discovery, 2019-02, Vol.18 (2), p.85-89

Mullard, Asher

2019

Volltextzugriff (PDF)

Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series

Clinical colorectal cancer, 2022-09, Vol.21 (3), p.267-271

2022

Volltextzugriff (PDF)

Recent advances in combinatorial drug screening and synergy scoring

Current opinion in pharmacology, 2018-10, Vol.42, p.102-110

2018

Volltextzugriff (PDF)

Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings

Expert opinion on drug safety, 2019-05, Vol.18 (5), p.381-392

2019

Volltextzugriff (PDF)

The BEETS (JACCRO CC-18) trial: an observational and translational study of

Future oncology (London, England), 2023-06, Vol.19 (17), p.1165-1174

2023

Volltextzugriff (PDF)

BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

ESMO Gastrointestinal Oncology, 2024-06, Vol.4, p.100066, Article 100066

2024

Volltextzugriff (PDF)

Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma

JAAD Case Reports, 2024-03, Vol.45, p.91-93

2024

Volltextzugriff (PDF)

Biophysical and docking study on the interaction of anticancer drugs encorafenib and binimetinib with human serum albumin

European journal of pharmaceutical sciences, 2023-10, Vol.189, p.106550-106550, Article 106550

2023

Volltextzugriff (PDF)

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers

Pharmacological research, 2018-09, Vol.135, p.239-258

Roskoski, Robert

2018

Volltextzugriff (PDF)

Melanoma: An update on systemic therapies

Journal of the American Academy of Dermatology, 2022-03, Vol.86 (3), p.515-524

2022

Volltextzugriff (PDF)

Encorafenib-induced eccrine squamous syringometaplasia

Annales de dermatologie et de vénéréologie, 2024-03, Vol.151 (1), p.103241-103241, Article 103241

2024

Volltextzugriff (PDF)

Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Pharmacological research, 2018-10, Vol.136, p.151-159

2018

Volltextzugriff (PDF)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

Cancer, 2020-02, Vol.126 (3), p.523-530

2020

Volltextzugriff (PDF)

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

Frontiers in pharmacology, 2024-09, Vol.15, p.1413154

2024

Volltextzugriff (PDF)

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Future oncology (London, England), 2024-02, Vol.20 (16), p.1047-1055

2024

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(121)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Encorafenib
(158)
Science & Technology
(116)
Life Sciences & Biomedicine
(114)
Binimetinib
(86)
Melanoma
(69)
Oncology
(58)
Mutation
(55)
Humans
(54)
Cetuximab
(43)
Proto-Oncogene Proteins B-Raf - Genetics
(38)
Vemurafenib
(37)
Dabrafenib
(36)
Braf
(34)
Colorectal Cancer
(33)
Pharmacology & Pharmacy
(31)
Metastasis
(28)
Trametinib
(23)
Kinases
(22)
Melanoma - Drug Therapy
(21)
Patients
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib

Properties of FDA-approved small molecule protein kinase inhibitors

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

Targeting ERK1/2 protein-serine/threonine kinases in human cancers

Pathological Complete Response after Beacon Regimen for Recurrent Colorectal Cancer of BRAF-Mutant—Report of a Case

BRAF inhibition and the spectrum of granulomatous reactions

2018 FDA drug approvals

Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series

Recent advances in combinatorial drug screening and synergy scoring

Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings

The BEETS (JACCRO CC-18) trial: an observational and translational study of

BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma

Biophysical and docking study on the interaction of anticancer drugs encorafenib and binimetinib with human serum albumin

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers

Melanoma: An update on systemic therapies

Encorafenib-induced eccrine squamous syringometaplasia

Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Suchergebnisse filtern